The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone

Pharmacotherapy

Volumn 18, Issue 1, 1998, Pages 9-15

  Hamelin, Bettina A ^a   Allard, Sylvie ^a   Laplante, Louis ^a   Miceli, Jeffrey ^a   Wilner, Keith D ^a   Tremblay, J ^a   LeBel, Marc ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; ZIPRASIDONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG HALF LIFE; DRUG SOLUBILITY; FAT INTAKE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PSYCHOMETRY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SEDATION; SOMNOLENCE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; ATTENTION; CROSS-OVER STUDIES; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PIPERAZINES; THIAZOLES;

EID: 0031984632     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983;6:S9-26
2. Klawans HL, Goetz CG, Perlik S. Tardive dyskinesia: review and update. Am J Psychiatry 1980;137:900-8.
3. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry 1981;138:297-309.
4. Tamminga CA, Lahti AC. The new generation of antipsychotic drugs. Int Clin Psychopharmacol 1997;11:73-6.
5. Seeger TF, Seymour P, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1997;275:101-13
6. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1997;124(1-2):57-73.
7. Howard HR, Lowe JA, Seeger TF, et al. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem 1996;39:143-8.
8. Howard HR, Prakash C, Seeger TF. Ziprasidone hydrochloride. Drugs Future 1994;19:560-3.
9. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin and dopamine affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-2.
10. Zorn SH, Seeger TF, Seymour PA. Ziprasidone (CP-88,059): preclinical pharmacology review. Jpn J Neuropsychopharmacol 1995;17:701-7.
11. Goldstein JM. Preclinical pharmacology of new atypical antipsychotics in late stage development. Expert Opin Invest Drugs 1995;4:291-8.
12. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-87.
13. 3H-labeled ziprasidone. Drug Metab Dispos 1997;25:206-18.
14. Miceli JJ, Hunt T, Cole MJ, Wilner KD. Pharmacokinetics of Cp-88,059 (CP) in healthy male volunteers following oral (PO) and intravenous (IV) administration [abstr]. Clin Pharmacol Ther 1994;55:142.
15. Wilner KD, Hansen RA, Johnson AC, Miceli JJ, Apseloff G, Gerber N. Single and multiple dose pharmacokinetics of ziprasidone in healthy males. Presented at the annual meeting of the American Psychiatric Association, New York, NY, May 4-9, 1996.
16. Schwartz F, Carr AC, Munich RL, Glauber S, Lesser B, Murray J. Reaction time impairment in schizophrenia and affective illness: the role of attention. Biol Psychiatry 1989; 25:540-8.
17. Evans FJ. Monitoring attention deployment by random number generation: an index to measure subjective randomness. Bull Psychonomic Soc 1978;12:35-8.
18. Horne RL, Evans FJ, Orne MT. Random number generation, psychopathology, and therapeutic change. Arch Gen Psychiatry 1982;39:680-3.
19. Neill WT, Westberry RL. Selective attention and the suppression of cognitive noise. J Exp Psychol 1987;13:327-34.
20. Beech A, Powell TJ, McWilliam J, Claridge GS. The effect of a small dose of chlorpromazine on a measure of "cognitive inhibition." Personality and Individual Differences 1990; 11:1141-5.
21. Laplante L, Everett J, Thomas J. Inhibition through negative priming with Stroop stimuli in schizophrenia. Br J Clin Psychol 1992;31:307-26.
22. Janiszewski JS, Fouda HG, Cole RO. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. J Chromatogr 1995; 668:133-9.
23. Rowland M, Tozer TN. Absorption and disposition kinetics. Therapeutic regimens. In: Rowland M, Tozer TN, eds. Clinical pharmacokinetics: concepts and application. Philadelphia: Lea & Febiger, 1989:9-100.
24. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrica 1965;52:591-611.
25. Miliken GA, Johnson DE. Analysis of messy data. In: Van Nostrand R, ed. Analysis of messy data. Belmont, CA: Lifetime Learning Publications, 1984:16-28.
26. Bolton S. Two-way analysis of variance (randomized blocks). In: Bolton S, ed. Pharmaceutical statistics. New York: Mercell Dekker, 1990:285-302.
27. Malagelada JR. Quantification of gastric solid-liquid discrimination during digestion of ordinary meals. Gastroenterology 1977;72:1264-7.
28. Welling PG. Effects of food on drug absorption. Pharmacol Ther 1989;43:425-41.
29. Lagrave M, Stahel E, Betschart B. The influence of various types of breakfast on chloroquine levels. Trans R Soc Trop Med Hyg 1985;79:559.
30. Liedholm H, Melander A. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther 1986;40:29-36.
31. Ali HM, Homeida MMA, Sulaiman SM, Bennett JL. Dietcontrolled blood levels of oltipraz in healthy male subjects. J Antimicrob Chemother 1984;13:465-70.
32. Axelson JE, Chan GLY, Kirsten EB, Mason WD, Lanham RC, Kerr CR. Food increases the bioavailability of propafenone. Br J Clin Pharmacol 1987;23:735-41.
33. Olanoff LF, Walle T, Cowrat TD, Walle UK, Oexmann MJ, Conradi EC. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther 1986;40:408-14.
34. Overdiek HWPM, Merkus WHM. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986;40:531-6.
35. Brandt JL, Castleman L, Ruskin HD, Grennwald J, Kelly JJ, Jones A. The effects of oral protein and glucose feeding on splanchnic blood flow and oxygen utilization in normal and cirrhotic subjects. J Clin Invest 1955;34:1017-25.
36. Gibaldi M, Feldman S. Mechanisms of surfactant effects on drug absorption. J Pharm Sci 1970;59:579-89.
37. Gibaldi M, Perrier D. One-compartment model. In: Gibaldi M, Perrier D, eds. Pharmacokinetics. New York: Marcel Dekker, 1982:1-43.
38. Ortiz A, Gershon S. The future of neuroleptic psychopharmacology. J Clin Psychiatry 1986;47(suppl 5):3-11.
39. MacLeod CM. Half a century of research on the Stroop effect: an integrative review. Psychol Bull 1991;109:163-203.
40. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992;15:426-32.
41. Freeman EW, Weinstock L, Rickels K, Sondheimer SJ, Coutifaris C. A placebo-controlled study of effects of oral progesterone on performance and mood. Br J Clin Pharmacol 1992;33:293-8.
42. de Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology 1992;107:352-8.